Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

New medication that can cut body weight by 23% could radically reduce the number of people who are obese. Tirzepatide is ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...